2025
SJR Q1
JCR Q1 · 5,6
OA
36 matched articles
SCIE
Journal detail
Cellular Oncology
- Publisher
- Springer Science and Business Media B.V.
- Country
- Netherlands · Western Europe
- Type
- journal
- ISSN
-
2211342822113436
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 1,561
- Quartile Q1
- H-Index 68
- Cites/doc 5,47
- Docs (3y) 337
- Cites (3y) 1.834
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 5,6
- 5Y JIF 5,8
- JCI 1,12
WoS indexes
- SCIE
Subject classification
Categories (SJR)
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 1,561 | 5,6 | 5,8 | 1,12 | Q1 | 68 |
| 2024 | Q1 | Q1 | 1,573 | 4,8 | 5,4 | 1,18 | Q1 | 62 |
| 2023 | Q1 | Q1 | 1,489 | 4,9 | 5,2 | 1,17 | Q1 | 62 |
| 2022 | Q1 | Q1 | 1,408 | 6,6 | 6,1 | 1,25 | Q1 | 62 |
| 2021 | Q1 | Q1 | 1,326 | 7,1 | 6,6 | 1,27 | Q1 | 62 |
| 2020 | Q1 | Q1 | 1,698 | 6,7 | 5,8 | 1,36 | Q1 | 62 |
| 2019 | Q1 | Q1 | 1,271 | 5,3 | 4,2 | 1,43 | Q1 | 62 |
| 2018 | — | Q1 | — | 5 | 3,5 | 1,35 | Q1 | — |
| 2017 | Q1 | Q1 | 1,465 | 4,8 | 3,7 | 1,22 | Q1 | 62 |
| 2016 | Q1 | Q1 | 1,199 | 3,8 | 3 | — | — | 62 |
| 2015 | Q1 | Q1 | 1,479 | 3,6 | 3,1 | — | — | 62 |
| 2014 | Q1 | Q1 | 1,328 | 3 | 2,8 | — | — | 62 |
| 2013 | Q1 | Q2 | 1,289 | 2,1 | 2,4 | — | — | 62 |
| 2012 | Q1 | Q2 | 0,954 | 2,4 | 2,8 | — | — | 62 |
| 2011 | — | Q1 | — | 3,1 | 3,3 | — | — | 62 |
| 2010 | — | Q1 | — | 3,2 | 3,2 | — | — | — |
| 2009 | — | Q1 | — | 4,2 | 3,4 | — | — | — |
| 2008 | — | Q1 | — | 3,4 | 3,1 | — | — | — |
| 2007 | — | Q1 | — | 4,2 | 3,8 | — | — | — |
| 2006 | — | Q1 | — | 3 | — | — | — | — |
| 2005 | — | Q1 | — | 4,2 | — | — | — | — |
| 2004 | — | — | — | — | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CELL BIOLOGY | SCIE | Q2 | Q1 | 68/207 |
| 2025 | ONCOLOGY | SCIE | Q1 | Q1 | 74/333 |
| 2025 | PATHOLOGY | SCIE | Q1 | Q1 | 5/89 |
| 2024 | CELL BIOLOGY | SCIE | Q2 | Q1 | 66/204 |
| 2024 | ONCOLOGY | SCIE | Q1 | Q1 | 75/328 |
| 2024 | PATHOLOGY | SCIE | Q1 | Q1 | 9/90 |
| 2023 | CELL BIOLOGY | SCIE | Q2 | Q1 | 67/205 |
| 2023 | ONCOLOGY | SCIE | Q1 | Q1 | 68/322 |
| 2023 | PATHOLOGY | SCIE | Q1 | Q1 | 11/88 |
| 2022 | CELL BIOLOGY | SCIE | Q2 | Q1 | 53/191 |
| 2022 | ONCOLOGY | SCIE | Q1 | Q1 | 50/241 |
| 2022 | PATHOLOGY | SCIE | Q1 | Q1 | 8/76 |
| 2021 | CELL BIOLOGY | SCIE | Q2 | Q1 | 58/195 |
| 2021 | ONCOLOGY | SCIE | Q1 | Q1 | 54/245 |
| 2021 | PATHOLOGY | SCIE | Q1 | Q1 | 9/77 |
| 2020 | CELL BIOLOGY | SCIE | Q2 | Q1 | 50/195 |
| 2020 | ONCOLOGY | SCIE | Q1 | Q1 | 49/242 |
| 2020 | PATHOLOGY | SCIE | Q1 | Q1 | 7/77 |
| 2019 | CELL BIOLOGY | SCIE | Q2 | Q1 | 53/195 |
| 2019 | ONCOLOGY | SCIE | Q1 | Q1 | 56/244 |
| 2019 | PATHOLOGY | SCIE | Q1 | Q1 | 9/78 |
| 2018 | CELL BIOLOGY | SCIE | Q2 | Q1 | 54/193 |
| 2018 | ONCOLOGY | SCIE | Q1 | Q1 | 49/230 |
| 2018 | PATHOLOGY | SCIE | Q1 | Q1 | 9/76 |
| 2017 | CELL BIOLOGY | SCIE | Q2 | Q1 | 56/190 |
| 2017 | ONCOLOGY | SCIE | Q1 | Q1 | 53/223 |
| 2017 | PATHOLOGY | SCIE | Q1 | Q1 | 10/79 |
| 2016 | CELL BIOLOGY | SCIE | Q2 | — | 78/190 |
| 2016 | ONCOLOGY | SCIE | Q2 | — | 74/217 |
| 2016 | PATHOLOGY | SCIE | Q1 | — | 14/79 |
| 2015 | CELL BIOLOGY | SCIE | Q2 | — | 82/187 |
| 2015 | ONCOLOGY | SCIE | Q2 | — | 74/213 |
| 2015 | PATHOLOGY | SCIE | Q1 | — | 13/79 |
| 2014 | CELL BIOLOGY | SCIE | Q3 | — | 107/184 |
| 2014 | ONCOLOGY | SCIE | Q2 | — | 94/211 |
| 2014 | PATHOLOGY | SCIE | Q1 | — | 18/76 |
| 2013 | CELL BIOLOGY | SCIE | Q4 | — | 139/185 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 129/203 |
| 2013 | PATHOLOGY | SCIE | Q2 | — | 36/76 |
| 2012 | CELL BIOLOGY | SCIE | Q3 | — | 121/185 |
| 2012 | ONCOLOGY | SCIE | Q3 | — | 106/197 |
| 2012 | PATHOLOGY | SCIE | Q2 | — | 28/77 |
| 2011 | CELL BIOLOGY | SCIE | Q3 | — | 94/181 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 77/196 |
| 2011 | PATHOLOGY | SCIE | Q1 | — | 17/79 |
| 2010 | CELL BIOLOGY | SCIE | Q3 | — | 95/178 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 64/185 |
| 2010 | PATHOLOGY | SCIE | Q1 | — | 16/76 |
| 2009 | CELL BIOLOGY | SCIE | Q2 | — | 56/162 |
| 2009 | ONCOLOGY | SCIE | Q1 | — | 40/166 |
| 2009 | PATHOLOGY | SCIE | Q1 | — | 10/71 |
| 2008 | CELL BIOLOGY | SCIE | Q2 | — | 74/157 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 56/143 |
| 2008 | PATHOLOGY | SCIE | Q1 | — | 16/69 |
| 2007 | CELL BIOLOGY | SCIE | Q2 | — | 48/156 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 39/132 |
| 2007 | PATHOLOGY | SCIE | Q1 | — | 9/66 |
| 2006 | CELL BIOLOGY | SCIE | Q2 | — | 78/156 |
| 2006 | ONCOLOGY | SCIE | Q2 | — | 50/127 |
| 2006 | PATHOLOGY | SCIE | Q1 | — | 11/64 |
| 2005 | CELL BIOLOGY | SCIE | Q2 | — | 43/153 |
| 2005 | ONCOLOGY | SCIE | Q1 | — | 29/123 |
| 2005 | PATHOLOGY | SCIE | Q1 | — | 5/66 |
| 2004 | CELL BIOLOGY | SCIE | — | — | — |
| 2004 | ONCOLOGY | SCIE | — | — | — |
| 2004 | PATHOLOGY | SCIE | — | — | — |